Sarcopenia Treatment Market By Treatment Type (Protein Supplement, Vitamin B12 Supplement, Vitamin D & Calcium Supplement, and Others), By  Administration (Oral, Parenteral, and Enteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Geography  

Sarcopenia Treatment Market was valued at USD 2775.2 million in 2023 and is poised to grow at a significant CAGR of 6.4% over 2024-2030. Sarcopenia refers to the loss of skeletal muscle mass or flesh as a result of an aging population. Sarcopenia is considered by a reduction in muscular size, relative weakness, lack of stamina, difficulties to mounting stairs, and poor balance. Sarcopenia can consequence in a worse quality of life as well as disability. Sarcopenia is caused primarily by malnutrition. In developing and poor countries, micronutrient-rich foods are consumed in low amounts, resulting in malnutrition. As a result, there is no recognized treatment for sarcopenia; nevertheless, proper nutrition and dietary supplements can help with the condition. A rising aging population, and deficiencies of vitamin D and vitamin B12 among a large section of people are primary factors driving the market growth of the sarcopenia treatment Market.

Additionally the increasing demand for protein and vitamin supplements also support to enhances the market demand. On the other hand, Sarcopenia Treatment Market is constrained by a lack of public knowledge of muscle loss, the high cost of protein supplements, and the lack of sarcopenia treatment medications. Nevertheless, numerous industries are focused on research and development efforts as well as clinical trials for age-related muscle mass loss, which is expected to growth of the Global sarcopenia treatment market with enormous potential prospects. Moreover, several pharmaceutical and food-processing businesses are making investments in the production of novel infant nutrition supplements to focus on the treatment of sarcopenia is further expected to boost the market growth.

Sarcopenia Treatment Market Recent Key Developments:

• In February 2022, MyMD Pharmaceuticals announced positive clinical data before the upcoming Phase II Trial of MYMD-1 drug candidates. MYMD-1 is a novel immunotherapy drug developed with the primary purpose of slowing the aging process, preventing sarcopenia and frailty, and extending a healthy lifespan.